Pharma Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
InSite Vision
InSite announces additional U.S. patent on azalide ophthalmic products
July 4th, 2006
InSite Vision Inc. (ISV) - an ophthalmic products company currently focused on developing therapies that treat ocular infection, glaucoma, and retinal diseases - announced the issuance of an additional U.S. patent on azalide drug products for use in ophthalmology by the United States Patent & Trademark Office. Azalides are a class of anti-infective drugs inclusive of azithromycin which is incorporated into InSite Vision's AzaSite product that recently completed two phase III clinical trials. "The issuance of this patent further extends and strengthens InSite Vision's intellectual property covering the AzaSite and the AzaSite franchise of products,"...
Source: Pharma Law Weekly (2006-07-04)
|
